SAHAJANAND MEDICAL TECHNOLOGIES IPO
SAHAJANAND MEDICAL TECHNOLOGIES is a MAINBOARD IPO with a current status of UPCOMING. The price band is 327 - 344. The issue opens on 15 OCT and closes on 19 OCT. The listing date is 23 OCT.
Price Band
327 - 344
Unofficial GMP
₹40
Lot Size
43 shares
Minimum Investment
₹14,792
SAHAJANAND MEDICAL TECHNOLOGIES IPO GMP
The latest available GMP is ₹40. Grey Market Premium is unofficial, may change frequently and does not guarantee the listing price, listing gains or investment returns.
Estimated Listing Price
₹384.00
Estimated Gain
+11.6%
SAHAJANAND MEDICAL TECHNOLOGIES IPO GMP History
40
11 OCT
40
12 OCT
SAHAJANAND MEDICAL TECHNOLOGIES IPO Details
- IPO Type
- MAINBOARD
- Status
- UPCOMING
- Price Band
- 327 - 344
- Issue Size
- ₹475.48 Cr
- Issue Type
- Book Build Issue
- Offer for Sale
- ₹475.48 Cr
- Face Value
- 1
- Lot Size
- 43
- Minimum Investment
- 14,792
- Exchange
- BSE , NSE
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead Managers
- Motilal Oswal Investment Advisors...
SAHAJANAND MEDICAL TECHNOLOGIES IPO Dates
- Open Date
- 15 OCT
- Close Date
- 19 OCT
- Allotment Date
- 21 OCT
- Refund Date
- 22 OCT
- Demat Credit Date
- 22 OCT
- Listing Date
- 23 OCT
SAHAJANAND MEDICAL TECHNOLOGIES IPO Subscription
- QIB
- --
- NII / HNI
- --
- Retail
- --
- Employee
- --
- Total Subscription
- --
SAHAJANAND MEDICAL TECHNOLOGIES IPO Valuation
- Market Cap (Post IPO)
- ₹3496.65 Cr.
- EPS
- 6.80
- P/E Ratio
- 6.80 5.94 P/E (x) 50.59
- ROE
- 2.07%
- ROCE
- 3.16%
- RONW
- 2.31%
- Debt / Equity
- 0.33%
- PAT Margin
- 4.29%
- EBITDA Margin
- 13.81%
SAHAJANAND MEDICAL TECHNOLOGIES Peer Comparison
| Peer | Revenue | PAT | EPS | P/E | ROE | RONW | Debt / Equity |
|---|---|---|---|---|---|---|---|
| POLY MEDICURE | 1,875.26* | -- | 31.79 | 51.40x | -- | 10.37% | -- |
| LAXMI DENTAL | 277.86* | -- | 5.27 | 36.35x | -- | 11.91% | -- |
SAHAJANAND MEDICAL TECHNOLOGIES IPO Market Lot
| Category | Lots | Shares | Investment |
|---|---|---|---|
| Retail Minimum | 1 | 43 | ₹14,792 |
| Retail Maximum | 13 | 559 | ₹1,92,296 |
| Small HNI | 14 | 602 | ₹2,07,088 |
| Big HNI | 68 | 2,924 | ₹10,05,856 |
SAHAJANAND MEDICAL TECHNOLOGIES IPO Reservation
- QIB
- 50%
- NII / HNI
- 15%
- Retail
- 35%
SAHAJANAND MEDICAL TECHNOLOGIES Promoter Holding and Anchor Allocation
- Pre-IPO Promoter Holding
- 40.82%
- Post-IPO Promoter Holding
- 36.20%
SAHAJANAND MEDICAL TECHNOLOGIES Company Overview
1. Sahajanand Medical Technologies Limited (SMT) is an Indian medical-device company specialising in cardiovascular and vascular-intervention products. 2. The company was established in 1999 as a partnership firm and incorporated as a private limited company in 2001. 3. Its primary products include coronary stents and coronary balloons used in the treatment of cardiovascular diseases. 4. The company also manufactures structural-heart devices, including transcatheter aortic valves (TAVI) and occluders. 5. Its other products include renal stents, peripheral drug-coated balloons and selected medical devices. 6. The company develops and manufactures regulated medical devices for use by hospitals and healthcare professionals. 7. Its products are distributed through hospitals, distributors and medical-device sales channels. 8. SMT has an international presence through subsidiaries and operations in markets including Europe, Russia and Latin America. 9. The company focuses on product development, clinical requirements, manufacturing quality and regulatory approvals. 10. Its Supraflex Cruz coronary stent is one of its key products and accounted for approximately 42.06% of FY2025 revenue. 11. Consolidated revenue from operations was approximately ₹1,024.88 crore in FY2025, compared with ₹901.60 crore in FY2024. 12. The company reported consolidated profit after tax of approximately ₹25.15 crore in FY2025, following a loss in FY2024.
SAHAJANAND MEDICAL TECHNOLOGIES Business Model
1. Coronary Stents: Manufactures stents used to help keep narrowed coronary arteries open after angioplasty. 2. Coronary Balloons: Supplies balloon catheters used in angioplasty and other coronary interventions. 3. Vascular Intervention: Develops medical devices used in minimally invasive procedures involving blood vessels. 4. Structural-Heart Devices: Manufactures devices for selected structural-heart conditions. 5. Transcatheter Aortic Valves: Develops TAVI products used in minimally invasive aortic-valve replacement procedures. 6. Occluders: Provides devices used to close certain abnormal openings or defects in the heart. 7. Renal Stents: Offers products used in selected urological and renal applications. 8. Peripheral Drug-Coated Balloons: Develops drug-coated balloon products for peripheral vascular interventions. 9. Medical-Device Manufacturing: Combines product development, manufacturing, quality control and regulatory compliance. 10. Hospital and Distributor Sales: Supplies products through healthcare institutions, distributors and medical-device channels. 11. International Business: Operates through subsidiaries and distribution networks serving multiple overseas markets. 12. Product Development: Focuses on expanding its product portfolio and developing devices for cardiovascular and structural-heart applications.
SAHAJANAND MEDICAL TECHNOLOGIES Objects of the Issue
1. Offer for Sale (OFS): The proposed IPO comprises an offer for sale of up to 2,76,44,231 existing equity shares. 2. Fresh Issue: No fresh issue of equity shares is proposed under the DRHP. 3. Company Proceeds: The company will not receive proceeds from the sale of shares. 4. Promoter Sale: Shree Hari Trust and Dhirajkumar Savjibhai Vasoya are among the selling shareholders. 5. Investor Sale: Existing investors, including Samara Capital Markets Holding Limited, Kotak Pre-IPO Opportunities Fund and NHPEA Sparkle Holding B.V., are also selling shareholders. 6. Business Expansion: The IPO itself will not provide additional capital for new manufacturing facilities, research or business expansion. 7. General Corporate Purposes: No proceeds from the OFS are allocated to the company for general corporate purposes. 8. Shareholder Liquidity: The offer allows existing shareholders to sell part of their holdings through the public market.
SAHAJANAND MEDICAL TECHNOLOGIES Strengths
1. Established Industry Presence: The company has experience in cardiovascular medical devices and vascular intervention products. 2. Specialised Product Portfolio: Its portfolio includes coronary stents, balloons, structural-heart devices and other specialised medical products. 3. Key Product Franchise: The Supraflex Cruz stent is an established product within the company's business portfolio. 4. Structural-Heart Expansion: Structural-heart products increased from 9.48% of revenue in FY2023 to 15.35% in FY2025. 5. Revenue Growth: Consolidated revenue increased from approximately ₹795.55 crore in FY2023 to ₹1,024.88 crore in FY2025. 6. International Presence: Overseas subsidiaries and distribution operations provide access to international medical-device markets. 7. Regulated Industry Expertise: Experience with medical-device regulatory requirements can support entry into markets with demanding product standards. 8. Product Development: Engineering and product-development capabilities support the company's specialised medical-device portfolio. 9. Operating Cash Flow: The company reported positive operating cash flow of approximately ₹73.52 crore in FY2025. 10. Diversification Opportunities: Expansion of structural-heart and peripheral-intervention products may broaden the product mix over time. 11. Healthcare Demand: Demand for cardiovascular procedures and minimally invasive treatments provides an underlying market for its products. 12. Manufacturing Capabilities: Established manufacturing and quality-control processes support the production of regulated medical devices.
SAHAJANAND MEDICAL TECHNOLOGIES Risks
1. Product Concentration: The Supraflex Cruz stent accounted for approximately 42.06% of FY2025 revenue, creating dependence on a single product. 2. Medical-Device Regulation: Changes in product approvals, clinical requirements or medical-device regulations could affect sales and market access. 3. Pricing Controls: Government price controls on certain medical devices may put pressure on product realisations and margins. 4. Import Dependence: Imported materials accounted for approximately 73.67% of purchases in FY2025, exposing the company to foreign-exchange and supply-chain risks. 5. Profitability Volatility: The company reported a consolidated loss in FY2024 before returning to a profit in FY2025. 6. Low Return on Equity: Return on equity was approximately 3.68% in FY2025, indicating relatively low returns on shareholder funds in that year. 7. Competition: The company competes with domestic and international medical-device manufacturers. 8. Product Approval Risk: Delays or failure in obtaining or maintaining regulatory approvals could restrict sales of existing or new products. 9. Product Liability: Defective devices or adverse clinical outcomes may lead to product recalls, legal claims or reputational damage. 10. Working-Capital Requirements: Net working-capital days were approximately 144 days in FY2025, indicating a relatively long operating cash cycle. 11. Borrowings: Total borrowings increased from approximately ₹132.18 crore in FY2023 to ₹224.96 crore in FY2025. 12. Legal and Regulatory Proceedings: The offer document discloses pending proceedings involving the company, subsidiaries and promoters. 13. International Business Risk: Overseas operations expose the company to regulatory differences, currency fluctuations and geopolitical changes. 14. Research and Development Risk: New medical devices require investment, testing and regulatory clearances, and commercial success is not guaranteed. 15. OFS Structure: The IPO is entirely an offer for sale, so the company will not receive proceeds to reduce debt or fund expansion. 16. Shareholder Exit: The offer allows existing promoter-group and financial investors to sell shares, which investors should assess alongside post-IPO ownership and governance disclosures.
SAHAJANAND MEDICAL TECHNOLOGIES Frequently Asked Questions
What is the SAHAJANAND MEDICAL TECHNOLOGIES IPO price band?
The SAHAJANAND MEDICAL TECHNOLOGIES IPO price band is 327 - 344.
What is the latest SAHAJANAND MEDICAL TECHNOLOGIES IPO GMP?
The latest available SAHAJANAND MEDICAL TECHNOLOGIES IPO GMP in the IPOWEB database is ₹40. GMP is unofficial and does not guarantee a listing gain.
When does the SAHAJANAND MEDICAL TECHNOLOGIES IPO open and close?
The SAHAJANAND MEDICAL TECHNOLOGIES IPO opens on 15 OCT and closes on 19 OCT.
When is the SAHAJANAND MEDICAL TECHNOLOGIES IPO allotment date?
The SAHAJANAND MEDICAL TECHNOLOGIES IPO allotment date is 21 OCT.
When is the SAHAJANAND MEDICAL TECHNOLOGIES IPO listing date?
The SAHAJANAND MEDICAL TECHNOLOGIES IPO listing date is 23 OCT.